A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 5, 2011, Pages 343-349

  McCormack, Pamela ^a   McNamara, Paul S ^a   Southern, Kevin W ^a  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DORNASE ALFA; PROMIXIN; UNCLASSIFIED DRUG;

ADOLESCENT; AEROSOL; ARTICLE; BREATHING MECHANICS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; FEEDBACK SYSTEM; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MALE; MEDICAL NEBULIZER; NEBULIZATION; NEBULIZER; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; SCHOOL CHILD; TARGET INHALATION MODE; TIDAL BREATHING MODE; TIME; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; INHALATION; MALE; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; PATIENT PREFERENCE; SALINE SOLUTION, HYPERTONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052503805     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.04.006     Document Type: Article

References (14)

1. Smyth A.R., Barbato A., Beydon N., Bisgaard H., de Boeck K., Brand P., et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J. Feb 2010, 35(2):247-265.
2. Geller D.E., Rubin B.K. Respiratory care and cystic fibrosis. Respir Care Jun 2009, 54(6):796-800.
3. O'Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med Oct 2009, 30(5):505-513.
4. Kesser K.C., Geller D.E. New aerosol delivery devices for cystic fibrosis. Respir Care 2009 Jun, 54(6):754-767. discussion 67-8.
5. McNamara P.S., McCormack P., McDonald A.J., Heaf L., Southern K.W. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros Jul 2009, 8(4):258-263.
6. Denyer J., Nikander K., Smith N.J. Adaptive Aerosol Delivery (AAD) technology. Expert Opin Drug Deliv Nov 2004, 1(1):165-176.
7. Denyer J., Dyche T. The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future. Journal of aerosol medicine and pulmonary drug delivery Apr 2010, 23(Suppl 1):S1-S10.
8. Denyer J., Prince I., Dixon E., Agent P., Pryor J., Hodson M. Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery Apr 2010, 23(Suppl 1):S29-S36.
9. Nikander K., Prince I., Coughlin S., Warren S., Taylor G. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. Journal of Aerosol Medicine and Pulmonary Drug Delivery Apr 2010, 23(Suppl 1):S37-S43.
10. Schulz K.F., Altman D.G., Moher D. CONSORT. Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010, 8:18.
11. Lancaster G.A., Dodd S., Williamson P.R. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004 May, 10(2):307-312.
12. Denyer J., Black A., Nikander K., Dyche T., Prince I. Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis. Journal of aerosol medicine and pulmonary drug delivery Apr 2010, 23(Suppl 1):S45-S54.
13. Avorn J. Regulation of devices. BMJ Nov 2 2010, 341. c5730.
14. Grasemann H., Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert opinion on emerging drugs Dec 2010, 15(4):653-659.